Please wait while the formulary information is being retrieved.
RUBRACA (rucaparib camsylate)
- BRCA-mutated metastat castration-resist prostate cancer
- cancer of ovary in patient with BRCA mutation
200 mg tablet
- 2 tablets (400 mg) by oral route every 12 hours
250 mg tablet
- 2 tablets (500 mg) by oral route every 12 hours
300 mg tablet
- 2 tablets (600 mg) by oral route every 12 hours
Default screening record
- 1 tablet (300 mg) by oral route every 12 hours
- 2 tablets (400 mg) by oral route every 12 hours
- 2 tablets (500 mg) by oral route every 12 hours
- 3 tablets (600 mg) by oral route every 12 hours
- 2 tablets (600 mg) by oral route every 12 hours
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- amiodarone
- amiodarone in dextrose,iso-osm
- artemether-lumefantrine
- Coartem
- Cordarone
- deferiprone
- disopyramide
- dronedarone
- droperidol
- Ferriprox
- Geodon
- Multaq
- Nexterone
- Norpace
- Norpace Cr
- Orap
- Pacerone
- pimozide
- thioridazine
- ziprasidone HCl
- ziprasidone mesylate
Severe
Moderate
- Ablavar
- alfuzosin
- amoxicil-clarithromy-lansopraz
- Anzemet
- Apokyn
- apomorphine
- arsenic trioxide
- Avelox
- Avelox Abc Pack
- Avelox In Nacl (iso-osmotic)
- Azilect
- bedaquiline
- Betapace
- Betapace Af
- Biaxin
- Biaxin Xl
- Biaxin Xl Pak
- Caprelsa
- Cipro
- Cipro In D5W
- Cipro Xr
- ciprofloxacin
- ciprofloxacin (mixture)
- ciprofloxacin in D5W
- clarithromycin
- clopidogrel
- crizotinib
- dasatinib
- Diskets
- dofetilide
- dolasetron
- Dolophine
- eribulin
- Erythrocin
- erythromycin
- erythromycin-sulfisoxazole
- ezogabine
- Fareston
- gadofosveset trisodium
- Halaven
- Haldol
- Haldol Decanoate
- haloperidol
- haloperidol decanoate
- haloperidol lactate
- Invega
- Invega Sustenna
- Invirase
- Istodax
- Juxtapid
- Kaletra
- Ketek
- lapatinib
- Levaquin
- Levaquin In 5 % Dextrose
- levofloxacin
- levofloxacin in D5W
- lomitapide
- lopinavir-ritonavir
- methadone
- Methadone Intensol
- Methadose
- moxifloxacin
- moxifloxacin in NaCl (iso-osm)
- Nexavar
- nilotinib
- norfloxacin
- Noroxin
- Noxafil
- Omeclamox-pak
- omeprazole-clarith-amoxicillin
- ondansetron
- ondansetron HCl
- ondansetron HCl (PF)
- paliperidone
- paliperidone palmitate
- pasireotide
- pazopanib
- Plavix
- posaconazole
- Potiga
- Prevpac
- propafenone
- Qualaquin
- quetiapine
- quinine sulfate
- rasagiline
- romidepsin
- Rythmol
- saquinavir mesylate
- Seroquel
- Seroquel Xr
- Signifor
- Sirturo
- sorafenib
- Sorine
- sotalol
- Sotalol Af
- Sprycel
- Tasigna
- telavancin
- telithromycin
- Tikosyn
- toremifene
- Trisenox
- Tykerb
- Uroxatral
- vandetanib
- vemurafenib
- Vfend
- Vfend Iv
- Vibativ
- voriconazole
- Votrient
- Xalkori
- Zelboraf
- Zofran
- Zofran Odt
- Zuplenz
- Congenital long QT syndrome
- Lactation
- Torsades de pointes
Contraindicated
- Myelodysplastic syndrome
- Pregnancy
- Prolonged QT interval
Severe
Moderate
- None
RUBRACA (rucaparib camsylate)
- BRCA-mutated metastat castration-resist prostate cancer
- cancer of ovary in patient with BRCA mutation
- Anemia
- Hypophosphatemia
- Increased alanine transaminase
- Increased aspartate transaminase
- Neutropenic disorder
- Thrombocytopenic disorder
- Abdominal distension
- Acute abdominal pain
- Anorexia
- Constipation
- Diarrhea
- Dysgeusia
- Dyspnea
- Fatigue
- General weakness
- Hypercholesterolemia
- Nausea
- Pharyngitis
- Stomatitis
- Vomiting
More Frequent
Severe
Less Severe
- Palmar-plantar erythrodysesthesia
- Dizziness
- Fever
- Peripheral edema
- Pruritus of skin
- Skin photosensitivity
- Skin rash
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myeloid leukemia
- Hypersensitivity drug reaction
- Myelodysplastic syndrome
- Myocardial ischemia
- Pneumonia
- Prolonged QT interval
- Sepsis
- Venous thrombosis
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Rucaparib
No safety and efficacy established.
- 1 Day – 18 Years
- No safety and efficacy established.
Rucaparib
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible
Contraindicated
Rucaparib
Mfg rec holding breastfeeding during & 2 weeks after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfg rec holding breastfeeding during & 2 weeks after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| BRCa-mutated metastat castration-resist prostate cancer | |
| C61 | Malignant neoplasm of prostate |
| Z19.2 | Hormone resistant malignancy status |
| Epithelial ovarian cancer with BRCA mutation | |
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.3 | Malignant neoplasm of bilateral ovaries |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| 0-9 | A-Z |
|---|---|
| C48.1 | Malignant neoplasm of specified parts of peritoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum |
| C56 | Malignant neoplasm of ovary |
| C56.1 | Malignant neoplasm of right ovary |
| C56.2 | Malignant neoplasm of left ovary |
| C56.3 | Malignant neoplasm of bilateral ovaries |
| C56.9 | Malignant neoplasm of unspecified ovary |
| C57.01 | Malignant neoplasm of right fallopian tube |
| C57.02 | Malignant neoplasm of left fallopian tube |
| C61 | Malignant neoplasm of prostate |
| Z19.2 | Hormone resistant malignancy status |
Formulary Reference Tool